While FDA has made tangible progress in reviewing and approving applications for biosimilars, there are still significant barriers for sponsors attempting to access and succeed in the market. In this webinar, panelists will review the current roadblocks to a robust biosimilar market in the US, including regulatory approval challenges, patent litigation risks, and whether there is hesitancy to accept biosimilars as equivalent to their biologics counterparts by doctors, patients, and payers. Panelists will also discuss proposed and potential changes to the current system that could improve access to and use of biosimilars

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Eva Temkin, Associate Director for Policy (Acting), Office of Therapeutic Biologics and Biosimilars, CDER, FDA
Rachel Turow, Associate General Counsel, Regulatory Law & Policy, Teva Pharmaceuticals USA, Inc. and Member, FDLI Board of Directors
Michael Werner, Partner, Holland & Knight LLP
Moderated by John R. Manthei, Partner, Latham & Watkins LLP

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content